Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.

@article{Hauschild2009ResultsOA,
  title={Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.},
  author={A. H. W. Hauschild and Sanjiv S. Agarwala and Uwe Trefzer and David Hogg and Caroline Robert and Peter Hersey and A. M. M. Eggermont and Stephan Grabbe and Rene C. Gonzalez and Jens Gille and Christian Peschel and Dirk Schadendorf and Claus Garbe and Steven J. O'Day and Adil I Daud and Josephine M White and Chenghua Xia and Kiran M. Patel and John Munn Kirkwood and Ulrich Keilholz},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2009},
  volume={27 17},
  pages={2823-30}
}
PURPOSE This phase III, randomized, double-blind, placebo-controlled study was conducted to evaluate the efficacy and safety of sorafenib with carboplatin and paclitaxel (CP) in patients with advanced melanoma who had progressed on a dacarbazine- or temozolomide-containing regimen. PATIENTS AND METHODS A total of 270 patients were randomly assigned to receive intravenous paclitaxel 225 mg/m2 plus intravenous carboplatin at area under curve 6 (AUC 6) on day 1 of a 21-day cycle followed by… CONTINUE READING
175 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 175 extracted citations

Similar Papers

Loading similar papers…